Cuba gradually resumes production of oral antibiotics.

 

Radio cadena Agramonte, Havana, August 21, 2021.- After the arrival of new supplies and raw materials, the Group of Biotechnology and Pharmaceutical Industries of Cuba (BioCubaFarma) gradually resumes the production of oral antibiotics destined for pharmacies throughout the national territory.

Rita María García Almaguer, director of Operations and Technology of this entity, told the press that since July the productive escalation of important drugs of this type began, such as amoxicillin, cephalexin, cefixime, cotrimoxazole (sulfaprim) and ciprofloxacin.

In the case of azithromycin, he said, we started its production both in powder for suspension and in capsules, but due to the current demand in hospitals for the treatment of COVlD-19, it will not be enough to take it to the pharmacy network in this area. We will also continue the production of metronidazole and, later, we anticipate the entry of oxacillin, added García Almaguer.

Despite the limitations, the directive explained that the manufacture of medicines for curing bacterial infections, which are used in Public Health institutions, such as amikacin, gentamicin and metronidazole in serum, is maintained.

He also stressed that the recovery began just a month ago when the active ingredients for the production of these precious pharmacological products arrived in the country, but given the current demand from patients, it will still take time to stabilize all production.

The Director of Operations and Technology of BioCubaFarma explained that the impact of the economic and financial blockade of the United States towards Cuba, together with the complex situation of international logistics generated by the new coronavirus pandemic, influenced the shortage of these drugs in the country.

On the other hand, the demand and consumption of these preparations in the face of the complex epidemiological scenario skyrocketed, and antibiotics such as cephalexin and azithromycin have had to double their production plan, the specialist commented.

He pointed out that of the 359 drugs that this entity must produce for the basic table of Cuban medicines, 251 have been covered in August, and emphasized that a decrease in the affected products is expected for the remainder of the year.

The Cuban pharmaceutical industry has not been paralyzed and the country has prioritized drugs for hospital use and around 70-80 percent of those destined for the protocols against COVID-19 have been guaranteed, said García Almaguer. 

Categoría
Eventos
RSS Minrex